To the best of our knowledge, the OPTIMA study will be the first study to evaluate tumor molecular profiling, UGT1A1 genotype and GUS activity as potential biomarkers for efficacy and toxicity of irinotecan-based systemic treatment in patients with advanced CRC. This evidence concerns the gene UGT1A1 and neoplasm.